Palvella Therapeutics, Inc. PVLA 深 沪
等待开盘 07-02 09:30:00 美东时间
138.26
-14.560
-9.53%
华盛通- 最 高150.08
- 今 开150.00
- 成交量 46.86万股
- 最 低 135.00
- 昨 收 152.82
- 总市值 19.83亿
- 52周最高 161.38
- 市盈率 静 --
- 换手率 3.27%
- 52周最低 25.80
- 委 比 66.24%
- 总股本 1434.28万
- 历史最高 161.38
- 量 比 0.93
- 振 幅 9.87%
- 历史最低 11.17
- 每 手 1
- 风险率 32.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy and Fast Track designations for QTORIN™ rapamycin, providing an expedited develo...
06-29 19:33
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
BERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell therapy modality where living, genetically engineered bacteria continuously prod...
06-09 20:43
Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphatic Malformations; On Track To Submit NDA In H2 Of 2026
Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection,
06-03 19:38
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026
In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA)
05-21 04:35
Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market
The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's common stock will continue to trade under its existing ticker symbol, "PVLA."The Nasdaq Global Market has higher initial and
05-13 19:33
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220
Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.
05-12 21:23
Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.Phase 2 single-arm,
05-04 19:36
Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April 20, 2026 (GLOBE
04-20 19:32
